Exhibiting at FOOD INGREDIENTS CHINA 2025

Zhejiang Medicine’s core competencies include:

• Vitamin E Production Leadership – One of the world’s largest producers of synthetic Vitamin E.
• Integrated API Manufacturing – Full production chain from raw intermediates to finished APIs.
• GMP-compliant Pharmaceutical Facilities – Produces human-grade antibiotics and specialty drugs.
• Advanced Carotenoid Extraction and Synthesis – Offers stable and bioavailable forms of lutein, beta-carotene, and lycopene.

The company holds a strategic advantage due to:

• Scale production capacity
• Diversified market reach across pharmaceuticals, nutrition, and animal health
• Strong R&D capabilities and intellectual property development

Target Market

Zhejiang Medicine supplies products to:

• Global dietary supplement brands
• Pharmaceutical manufacturers and hospitals
• Veterinary product formulators
• Functional food and beverage companies

The company exports to over 60 countries, including:

• United States
• Germany
• India
• Brazil
• Japan
• Russia

Manufacturing Capabilities and Infrastructure

The company operates multiple production bases in Zhejiang Province with:

• GMP-certified pharmaceutical plants
• High-capacity vitamin and carotenoid production lines
• Dedicated R&D centers for drug synthesis, fermentation, and formulation development

Key facilities include:

• Shaoxing Base (Pharmaceutical APIs and preparations)
• Xinchang Base (Nutrition and feed-grade vitamins)
• Tongxiang Base (High-tech development and pilot production)

Zhejiang Medicine invests heavily in automation and environmental protection measures across its plants.

Certifications and Compliance

Zhejiang Medicine’s facilities and products comply with international standards:

• GMP (China, EU, US FDA compliant facilities)
• ISO 9001 Quality Management
• ISO 14001 Environmental Management
• OHSAS 18001 Occupational Health & Safety
• FAMI-QS and Feed Additive Approvals
• CEP (Certificate of Suitability to Monographs of the European Pharmacopoeia)
• FDA DMFs (Drug Master Files) and COS

Financial and Shipment Records

Zhejiang Medicine Co., Ltd. is listed on the Shanghai Stock Exchange (Stock Code: 600216) and reported the following key financial metrics:

• 2022 Revenue: Over RMB 6.9 billion (~USD 1 billion)
• Net Profit: RMB 520+ million
• Vitamin E exports: Over 20,000 MT annually, making it a top 3 global exporter

According to shipment data from Volza and ImportYeti:

• Frequent export shipments of Coenzyme Q10, synthetic Vitamin E, and APIs to North America and Europe
• Major buyers include pharmaceutical companies, nutritional product manufacturers, and chemical distributors

Major Achievements

• Among the top global producers of Vitamin E and CoQ10
• Developed indigenous production processes for high-purity APIs such as Vancomycin
• Recognized as a National Key High-Tech Enterprise in China
• Collaborated with research institutions for novel drug delivery systems and anti-infective research

Customer Testimonials

“Zhejiang Medicine’s synthetic Vitamin E is a benchmark in quality and price competitiveness. We’ve sourced it for over a decade.”
— Global Sourcing Manager, Nutraceutical Brand, USA

“Their APIs meet strict EU compliance standards and are always delivered with complete documentation and regulatory support.”
— Regulatory Affairs Director, Pharmaceutical Company, Germany

Zhejiang Medicine Co., Ltd. remains a cornerstone of China’s health industry exports, blending pharmaceutical excellence with life science innovation to serve global human and animal wellness.